Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876645 | 0.88 | — | — | |
| SCHEMBL21730404 | 0.88 | — | — | |
| SCHEMBL50733 | 0.88 | — | — | |
| SCHEMBL17188945 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL29920122 | 0.86 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL611862 | 0.86 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL271156 | 0.86 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL24240867 | 0.79 | — | — | |
| SCHEMBL16242450 | 0.79 | — | — | |
| SCHEMBL3936594 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122610-A1 | THERAPEUTIC COMBINATIONS AND METHODS FOR 5-HT3 RECEPTOR MODULATORS IN TREATING VARIOUS DISORDERS | SEROTONIX LLC (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023173017-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023086959-A1 | FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-8058276-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| WO-2011008572-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2118109-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7547690-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008112473-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | CHRNB2 4022/4885CHRNA3 4136/4885CHRNA4 4509/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | CHRNB2 4663/4885CHRNA3 4773/4885CHRNA4 4859/4885 |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | CHRNB2 4673/4885CHRNA3 4620/4885CHRNA4 4848/4885 |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | CHRNB2 458/4885CHRNA3 95/4885CHRNA4 269/4885 |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, NR1H4 | CHRNB2 4842/4885CHRNA3 4724/4885CHRNA4 4838/4885 |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | CHRNB2 4298/4885CHRNA3 4068/4885CHRNA4 4329/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | CHRNB2 4663/4885CHRNA3 4773/4885CHRNA4 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.